Breast Cancer Clinical Trial
Prevention of Capsular Contracture Using Trental and Vitamin E
Summary
The main purpose of this research study is to determine if the use of Trental and Vitamin E will decrease the incidence and severity of contractures (shrinking and or hardening of tissue surrounding the implant) associated with breast implant reconstruction following radiation treatment. Another goal is to find out the impact that Trental and Vitamin E have on implant loss or need for surgical intervention in the setting of chest wall radiation after reconstruction. In addition, the investigators want to evaluate the patient's sense of well being and quality of life.
Full Description
This is a single center, 18-month study in which 30 women will receive Trental (pentoxifylline) 400 milligrams three times a day in combination with vitamin E, 400 international units orally twice daily for six months. Subjects will begin the treatment regimen within four weeks after completion of radiation treatment and will remain on the study drugs for six months. Following completion of active treatment, all subjects will enter the twelve-month observational phase of the trial in which they will be evaluated for changes in breast tissue using the following objective tools: Bakers Grade Assessment, Visual Analog Scale (VAS), implant revision or loss, breast photographs, adverse event assessment and the Quality of Life tool (SF-12).
Eligibility Criteria
Inclusion Criteria:
Female subjects
> 18 years of age
Expected survival at least > 6 months
Undergone mastectomy with expander or implant reconstruction > 3 weeks before radiation therapy
Completed chest wall irradiation in the past two weeks
Willing to stop herbal medications as directed by physician
Willing to stop daily use of supplemental vitamin E (Multivitamin with vitamin E component is acceptable)
Willing to travel to a Legacy Health System facility
Agree to attend study visits outside of standard of care visits
Normal PT-INR for subjects taking Coumadin
Exclusion Criteria:
< 18 years of age
Pregnant or lactating
Have final implant placed < 3 weeks before start of radiation therapy
Have evidence of ongoing infection or implant exposure before start of radiation therapy
Radiation completed more than 16 days prior to study start
Retinitis Pigmentosa
Unable to comply with protocol
Unable to provide written informed consent
Unwilling or unable to stop supplemental vitamin E
PT-INR outside of acceptable range for subjects taking Coumadin
Investigator does not believe study participation, for any reason is in the best interest of the patient
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Portland Oregon, 97210, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.